- Home
- RNG vs MRUS Comparison
RNG vs MRUS Comparison
Compare RNG & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNG
- MRUS
- Stock Information
- Founded
- RNG 1999
- MRUS 2003
- Country
- RNG United States
- MRUS Netherlands
- Employees
- RNG N/A
- MRUS N/A
- Industry
- RNG EDP Services
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- RNG Technology
- MRUS Health Care
- Exchange
- RNG Nasdaq
- MRUS Nasdaq
- Market Cap
- RNG 3.1B
- MRUS 3.6B
- IPO Year
- RNG 2013
- MRUS 2016
- Fundamental
- Price
- RNG $36.51
- MRUS $47.00
- Analyst Decision
- RNG Buy
- MRUS Strong Buy
- Analyst Count
- RNG 15
- MRUS 10
- Target Price
- RNG $40.73
- MRUS $86.70
- AVG Volume (30 Days)
- RNG 1.3M
- MRUS 434.2K
- Earning Date
- RNG 11-07-2024
- MRUS 10-31-2024
- Dividend Yield
- RNG N/A
- MRUS N/A
- EPS Growth
- RNG N/A
- MRUS N/A
- EPS
- RNG N/A
- MRUS N/A
- Revenue
- RNG $2,357,154,000.00
- MRUS $35,932,000.00
- Revenue This Year
- RNG $9.88
- MRUS N/A
- Revenue Next Year
- RNG $7.77
- MRUS $52.49
- P/E Ratio
- RNG N/A
- MRUS N/A
- Revenue Growth
- RNG 9.33
- MRUS N/A
- 52 Week Low
- RNG $26.98
- MRUS $22.26
- 52 Week High
- RNG $40.98
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- RNG 48.23
- MRUS 33.10
- Support Level
- RNG $34.13
- MRUS $42.30
- Resistance Level
- RNG $36.04
- MRUS $45.76
- Average True Range (ATR)
- RNG 1.60
- MRUS 2.23
- MACD
- RNG -0.40
- MRUS -0.91
- Stochastic Oscillator
- RNG 10.66
- MRUS 17.11
About RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.